Ireland
--:--IST
Recruiting Not applicable

Robot-Assisted Gait Training vs NMES in Parkinson's Disease

NCT07589296 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-04-15
Last updated
2026-05-15

Condition(s) studied

Parkinson Disease (PD)

Investigational drug(s) / intervention(s)

Quadriceps Neuromuscular Electrical Stimulation (NMES)robot -assisted gait training

Quadriceps Neuromuscular Electrical Stimulation (NMES): Quadriceps neuromuscular electrical stimulation (NMES) applied to the quadriceps muscle in addition to a standard rehabilitation program including posture exercises, balance and coordination training, relaxation, and functional gait training in patients with Parkinson's disease. This intervention specifically targets improvement of quadriceps muscle strength and neuromuscular activation.

robot -assisted gait training: Robot-assisted gait training applied in addition to a standard rehabilitation program including posture exercises, balance and coordination training, relaxation, and functional gait training in patients with Parkinson's disease. This intervention is designed to improve gait performance, balance, and functional mobility.

Study summary

This prospective, randomized, assessor-blinded clinical trial aims to compare the effects of robot-assisted gait training and quadriceps neuromuscular electrical stimulation (NMES) when added to a standard exercise rehabilitation program in patients with Parkinson disease.

Participants will be randomly assigned to two parallel groups. Both groups will receive a standard rehabilitation program, while one group will additionally undergo robot-assisted gait training and the other group will receive quadriceps NMES. The interventions will be administered five days per week for six weeks.

Clinical outcomes, including balance, functional mobility, gait performance, and disease severity, will be evaluated at baseline, post-treatment, and follow-up (week 14). In addition, ultrasound-based assessments of quadriceps muscle thickness and cross-sectional area will be performed to investigate muscle adaptations.

The results of this study are expected to provide comparative evidence regarding the effectiveness of these two rehabilitation approaches and contribute to optimizing rehabilitation strategies in Parkinson disease.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Parkinson's disease according to established clinical criteria * Age between 40 and 80 years * Hoehn and Yahr stage II-III * Ability to walk independently with or without assistive devices * Stable medical treatment for at least 4 weeks prior to study enrollment * Ability to understand and follow instructions * Willingness to participate and provide written informed consent Exclusion Criteria: * Severe cognitive impairment or inability to follow instructions * Hoehn and Yahr stage IV-V Parkinson's disease * Severe musculoskeletal disorders affecting gait (e.g., advanced osteoarthritis, recent fracture) * History of lower extremity surgery within the last 6 months * Severe cardiovascular or respiratory disease limiting exercise participation * Presence of other neurological disorders affecting mobility (e.g., stroke, multiple sclerosis) * Contraindications to electrical stimulation (e.g., pacemaker, implanted electronic devices) * Skin lesions or infections at electrode placement sites * Participation in another structured rehabilitation program within the last 3 months

Primary outcome measure(s)

  • Timed Up and Go Test (TUG) — Baseline, 6 weeks, and 14 weeks
    Assessment of functional mobility and balance using the Timed Up and Go test in patients with Parkinson's disease. Lower completion times indicate better functional mobility.

Trial sites (1)

FacilityCityRegionStatus
Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey Küçükçekmece Istanbul Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07589296 on ClinicalTrials.gov ↗ ← All trials in Turkey